MMP2 Polymorphisms and Colorectal Cancer Susceptibility in a Chinese Han Population

Abstract

Colorectal cancer (CRC) is among the most common cancers worldwide and an important cause of cancer-related death. Inherited genetic variation plays a vital role in the occurrence and development of CRC. The aim of this study was to evaluate the association of single nucleotide polymorphisms (SNPs) in MMP2 with CRC risk. Patients and Methods: Three candidates, MMP2 SNPs, rs1053605, rs243849, and rs14070, were selected and genotyped using the Agena MassARRAY RS1000 system, and their association with risk of CRC was evaluated in 663 CRC cases and 663 healthy controls by calculating odds ratio (OR) with 95% confidence interval (95% CI) values. Results:The minor allele of rs243849 (T) was significantly less frequent in cases than controls (p = 0.021), and this SNP was associated with a decreased risk of CRC under co-dominant (p = 0.033), dominant (p = 0.021), and log-additive (p = 0.017) models, after adjusting for confounding factors. After stratification, rs243849 was found to be protective against CRC in patients who were non-smoking, consumed alcohol, and were ≥60 years old (p < 0.05). Conversely, rs1053605 was associated with disease occurrence in patients with CRC who consumed alcohol and were <60 years old (p < 0.05). Furthermore, rs1053605 genotype was associated with an increased risk of colon cancer (p < 0.05), while that of rs243849 was associated with a decreased risk of rectal cancer (p < 0.05). The rs1053605-rs243849 CT haplotype exhibited a protective role in CRC risk, following adjustment for confounders (p = 0.014). The rs14070 SNP was not associated with CRC risk. Finally, the false discovery rate (FDR) method was used to validate the study results. Conclusion: Overall, the MMP2 gene polymorphisms, rs243849 and rs1053605, may be useful for predicting CRC progression.

Current Advances of Nanomaterial-Based Oral Drug Delivery for Colorectal Cancer Treatment

“…Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases known for their involvement in cancer prognosis [53] and have been widely explored for drug delivery and imaging [54]. According to a clinical statistical trial in a Chinese population, MMP variants are potential genetic markers for CRC risk [55]. Rashidzadeh et al [56] prepared enzyme-responsive hydrogels containing methotrexate (MTX) and chloroquine (CQ) in polymethylmethacrylic acid (PMAA), catalyzing the drug release in the presence of proteolytic enzymes.…”

A potential tumor marker: Chaperonin containing TCP‑1 controls the development of malignant tumors (Review)

“…CRC is a multifactorial disease involving genetic, environmental and lifestyle risk factors ( 103 ). The high heritability and frequent recurrence of CRC leads to considerable mortality and the association with poor prognosis ( 104 ). At 2020, there were >1.9 million new cases of CRC (including anal) and nearly 935,000 mortalities in worldwide ( 105 ).…”

Rectal Cancer: Are 12 Lymph Nodes the Limit?

“…Makar et al demonstrated that the rs20417 polymorphism in the cyclooxygenase 2 ( COX-2 ) gene is associated with a higher risk of rectal cancer [ 5 ]. Conversely, Liu et al showed that polymorphism rs24384 in the matrix metallopeptidase 2 ( MMP2 ) gene is associated with a decreased risk of rectal cancer [ 6 ]. Similarly, other polymorphisms that are related to decreased risk of rectal cancer are in the methylenetetrahydrofolate reductase ( MTHFR ) gene (rs1801133) [ 7 ] and the peroxisome proliferators-activated receptor gamma ( PPARγ ) gene (rs1801282) [ 8 ].…”